Dana-Farber researchers to present findings at 2025 San Antonio Breast Cancer Symposium
Dana-Farber Cancer Institute Faculty Among World's Most Highly Cited Researchers
Dana-Farber Research Points to Potential Gene Therapy Improvements
Three Ways Research Could Improve Pancreatic Cancer Treatment
FDA Approves Menin Inhibitor for Patients With Acute Leukemia With NPM1 Mutation, Backed by Dana-Farber Science
Pan-Mass Challenge Raises Record $78 Million for Dana-Farber Cancer Institute
Bringing Specialists Together: Tandem Leukemia and Stem Cell Transplant Consults
Dana-Farber Research Uncovers Potential Targeted Therapy for Endometrial Cancer
Blood Test Guides Post-Surgical Immunotherapy for Muscle-Invasive Bladder Cancer
ADC Improves Outcomes for Patients with Advanced Triple-Negative Breast Cancer Who are Ineligible for Immune Checkpoint Inhibitors
Novel Treatment Combination Improves Progression-Free Survival in Metastatic, Estrogen-Receptor-Positive HER-2-Negative Breast Cancer
Chemotherapy Combination Boosts Overall Survival in Patients with EGFR-mutant Non-Small Cell Lung Cancer
Breast, Lung, and Bladder Cancer Phase 3 Trials led by Dana-Farber Presented at ESMO Congress 2025
Dana-Farber/Boston Children's Ranked Among the Best Pediatric Cancer Programs in the Nation for 19th Year in a Row
Innovative Roswell Park Radiation Therapy Protocol in Lung Cancer to Be Highlighted at ASTRO Annual Meeting
Showing 1 - 15 of 1043 results
Previous| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ...70 |Next
Cancer
Cardiology
Gastroenterology
Neurology
OBGYN
Orthopedics
Pediatrics
BroadcastMed News
Dermatology
Diabetes & Endocrinology
Infectious Diseases
Ophthalmology
Optometry
Otolaryngology
Pulmonology
Surgery
Urology
About
Solutions
Resources
Contact
person Sign In / Create Account
